| BASILEA |
BASILEA |
92%
|
In December 2024, we entered into an exclusive distribution and license agreement with Basilea, under which we were granted exclusive marketing rights to ZEVTERA ® in the U.S. |
| BASILEA-PHARMACEUTICA-LTD |
BASILEA-PHARMACEUTICA-LTD |
62%
|
ents. 102 Table of Contents INNOVIVA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Year Ended December 31, 2024 2023 2022 Cash flows from operating activities Net income $ 23,392 $ 179,7… |
| ENTASIS-THERAPEUTICS-HOLDINGS-INC |
ENTASIS-THERAPEUTICS-HOLDINGS-INC |
62%
|
ents. 102 Table of Contents INNOVIVA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Year Ended December 31, 2024 2023 2022 Cash flows from operating activities Net income $ 23,392 $ 179,7… |
| EVEREST-MEDICINES-LIMITED |
EVEREST-MEDICINES-LIMITED |
62%
|
ing authorizations for the product candidate in their respective territories. 116 Table of Contents INNOVIVA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) PAION Pharma GmbH Pursuant to… |
| GATE-NEUROSCIENCES-INC |
GATE-NEUROSCIENCES-INC |
62%
|
ic interests in other healthcare companies. Our focus on capital allocation and shareholder value maximization has led our company to a meaningful transformation over the last two years. In 2022 our … |
| GLAXO-GROUP-LIMITED |
GLAXO-GROUP-LIMITED |
62%
|
ents. 102 Table of Contents INNOVIVA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Year Ended December 31, 2024 2023 2022 Cash flows from operating activities Net income $ 23,392 $ 179,7… |
| HUMANWELL-HEALTHCARE-GROUP |
HUMANWELL-HEALTHCARE-GROUP |
62%
|
ing authorizations for the product candidate in their respective territories. 116 Table of Contents INNOVIVA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) PAION Pharma GmbH Pursuant to… |
| INC-IMAGINAB-INC |
INC-IMAGINAB-INC |
62%
|
ation to absorb losses of, or the right to receive benefits from, TRC. We held 15 % ownership interest of TRC. The primary source of revenue for TRC is the royalties generated from the net sales of T… |
| LA-JOLLA-PHARMACEUTICAL-COMPANY |
LA-JOLLA-PHARMACEUTICAL-COMPANY |
62%
|
ents. 102 Table of Contents INNOVIVA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Year Ended December 31, 2024 2023 2022 Cash flows from operating activities Net income $ 23,392 $ 179,7… |
| OPERATIONS-INNOVIVA-INC |
OPERATIONS-INNOVIVA-INC |
62%
|
ents. 102 Table of Contents INNOVIVA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Year Ended December 31, 2024 2023 2022 Cash flows from operating activities Net income $ 23,392 $ 179,7… |
| PAION-AG |
PAION-AG |
62%
|
ing authorizations for the product candidate in their respective territories. 116 Table of Contents INNOVIVA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) PAION Pharma GmbH Pursuant to… |
| PAION-DEUTSCHLAND-GMBH |
PAION-DEUTSCHLAND-GMBH |
62%
|
ing authorizations for the product candidate in their respective territories. 116 Table of Contents INNOVIVA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) PAION Pharma GmbH Pursuant to… |
| PAION-PHARMA-GMBH-EVEREST-MEDICINES-LIMITED |
PAION-PHARMA-GMBH-EVEREST-MEDICINES-LIMITED |
62%
|
ing authorizations for the product candidate in their respective territories. 116 Table of Contents INNOVIVA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) PAION Pharma GmbH Pursuant to… |
| THERAVANCE-RESPIRATORY-COMPANY-LLC |
THERAVANCE-RESPIRATORY-COMPANY-LLC |
62%
|
ents. 102 Table of Contents INNOVIVA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Year Ended December 31, 2024 2023 2022 Cash flows from operating activities Net income $ 23,392 $ 179,7… |
